WCLC 2025 - Posters & ePosters-P1.07.05 Real-World Biomarker Testing and Treatment Initiation in Patients With Resected Early-Stage NSCLC (eNSCLC) in the US and UK

P1.07.05 Real-World Biomarker Testing and Treatment Initiation in Patients With Resected Early-Stage NSCLC (eNSCLC) in the US and UK

Back to course

Pdf Summary

This retrospective study evaluated real-world biomarker testing (EGFR/ALK) and treatment initiation in patients with resected early-stage non-small cell lung cancer (eNSCLC) in the US and UK, using the Flatiron Health Research Databases. The study included patients diagnosed with stage IB-IIIA NSCLC between January 1, 2020, and July 1, 2024, who underwent surgical resection. The primary focus was on whether biomarker testing was performed and its association with patient demographics, clinical characteristics, timing relative to surgery, and systemic therapy (neoadjuvant or adjuvant).<br /><br />Findings showed that biomarker testing has increased over time, with more than half of resected eNSCLC patients tested by the end of the study period in both countries. Testing was more common among patients diagnosed recently, with higher cancer stage and higher socioeconomic status, indicating possible disparities. Importantly, the timing of surgery and systemic treatment did not differ significantly between tested and untested groups, suggesting that biomarker testing integration did not delay treatment initiation.<br /><br />Median times from diagnosis to surgery and systemic therapy were similar regardless of biomarker testing status. In the US, median time from diagnosis to surgery ranged from about 21 to 140 days depending on treatment timing and testing, and time to start of earliest systemic therapy was between 26 to 103 days. Comparable timing was observed in the UK cohort.<br /><br />Multivariable logistic regression highlighted factors influencing the likelihood of receiving early biomarker testing, supporting that monitoring and improving testing uptake and access remain important. The study concludes that adoption of EGFR/ALK biomarker testing in early-stage NSCLC is increasing in the US and UK without negatively impacting treatment timing, but further research is needed to address barriers, expand to other biomarkers and countries, and assess outcomes.

Asset Subtitle

Samantha Reiss

Meta Tag

Speaker Samantha Reiss

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

biomarker testing

EGFR

ALK

early-stage non-small cell lung cancer

eNSCLC

resected NSCLC

Flatiron Health Research Databases

treatment initiation timing

neoadjuvant therapy

adjuvant therapy